Praziquantel kills the worms but cannot reverse the fibrosis already embedded in the liver
For the 254 million people living with schistosomiasis — a parasitic disease that slowly turns the liver to scar tissue — medicine has long offered only a partial answer. Praziquantel can kill the worms, but it cannot undo the damage they leave behind. Now, researchers in Taiwan have found that naringenin, a compound drawn from the ordinary citrus fruit, may address precisely what the existing drug cannot: the fibrosis, inflammation, and oxidative injury that persist long after the parasite is gone. It is a reminder that some of the most consequential medicines may already exist in nature, waiting to be understood.
- Schistosomiasis kills roughly 15,000 people each year and puts 600 million more at risk, yet the only approved drug cannot reverse the liver scarring that drives patients toward cirrhosis and death.
- In laboratory dishes, naringenin damaged the outer surface of Schistosoma worms, halted their reproduction, and killed them at rates matching or exceeding praziquantel — raising hopes for a new weapon against the parasite itself.
- When the compound was tested in living mice, its worm-killing power fell short — parasite counts and trapped eggs remained largely unchanged — exposing the gap that always exists between a petri dish and a living body.
- Yet the mice treated with naringenin showed dramatically less liver fibrosis, lower inflammatory markers, and measurably better liver function, suggesting the compound's real power lies in healing the organ rather than eliminating the invader.
- Researchers now propose a combination strategy — praziquantel to kill the worms, naringenin to reverse the damage — a theoretical but evidence-backed path toward making schistosomiasis a disease that can be not just treated, but undone.
Schistosomiasis is a disease of quiet devastation. The Schistosoma parasite lives in blood vessels and deposits eggs in the liver, where they trigger a slow inflammatory siege that hardens the organ into scar tissue. Without intervention, fibrosis advances to cirrhosis and death. The World Health Organization estimates roughly 15,000 deaths each year, with nearly 600 million people at risk across the developing world. For decades, the only available drug has been praziquantel — effective at killing adult worms, but powerless against the fibrosis already embedded in the liver.
Researchers at Tzu Chi University in Taiwan turned to naringenin, a flavonoid found in oranges, lemons, and grapefruits, long studied for its anti-inflammatory and antioxidant properties. In laboratory tests, the compound proved striking: when adult worms were exposed to naringenin, they lost motility, suffered visible damage to their protective outer surface, and stopped reproducing before dying — results that matched or exceeded praziquantel in the dish.
The picture in living mice was more nuanced. Infected animals given naringenin orally for two weeks did not show meaningful reductions in worm or egg counts — the compound's parasite-killing power did not fully survive the complexity of a living body. But their livers told a different story. Treated mice showed significantly less fibrosis, improved liver function in blood tests, and reduced tissue injury under the microscope.
The mechanism pointed to naringenin's effect on the molecular machinery of scarring: it suppressed transforming growth factor-beta, the key signal that activates collagen-producing stellate cells, and reduced inflammatory cytokines and oxidative stress markers throughout the liver.
The researchers propose that neither drug alone is sufficient, but together they may be. Praziquantel could eliminate the parasites while naringenin reverses the damage they leave behind — a combination that remains theoretical but is now grounded in laboratory evidence. For a disease long understood as a sentence of progressive organ failure, that possibility represents a meaningful shift in what recovery might look like.
Schistosomiasis is a parasitic disease that quietly devastates the livers of more than 250 million people worldwide. The parasite, Schistosoma, lives in blood vessels and lays eggs that accumulate in the liver, triggering a cascade of inflammation that hardens the organ into scar tissue—a condition called fibrosis. Left untreated, this scarring progresses to cirrhosis and death. The World Health Organization counts roughly 15,000 deaths annually from the disease, with nearly 600 million people in developing countries at risk of infection. For decades, doctors have relied on a single drug, praziquantel, to kill the adult worms. But praziquantel has a critical limitation: it cannot reverse the fibrosis already embedded in the liver, nor can it prevent the disease from advancing in patients who have already been infected.
Researchers at Tzu Chi University in Taiwan set out to explore whether a compound found in citrus fruit might offer what praziquantel cannot. Naringenin is a flavonoid—a type of plant chemical abundant in oranges, lemons, and grapefruits—that has shown promise in laboratory studies for its anti-inflammatory and antioxidant properties. The team wanted to know whether naringenin could both kill the parasites themselves and reverse the liver damage they cause.
In petri dishes, the results were striking. When adult Schistosoma worms were exposed to naringenin at concentrations of 100 and 200 micrograms per milliliter, the worms lost their ability to move and eventually died. Scanning electron microscopy revealed that naringenin damaged the worms' outer surface, the tegument, which the parasites normally use to hide from the immune system. Female worms stopped laying eggs even when they were still technically alive, suggesting the compound disrupted their reproductive machinery before killing them outright. These in-vitro results matched or exceeded the performance of praziquantel in the lab.
But the real test came in living mice. Researchers infected 45 male BALB/c mice with Schistosoma cercariae—the larval stage of the parasite—and divided them into three groups: uninfected controls, infected mice left untreated, and infected mice given naringenin orally at 50 milligrams per kilogram of body weight for two weeks starting eight weeks after infection. At ten weeks post-infection, all animals were euthanized and their livers examined.
The in-vivo results were more complicated. Naringenin did not significantly reduce the number of adult worms in the infected mice, nor did it lower the count of eggs trapped in liver and intestinal tissue. The compound's worm-killing power, so evident in the dish, did not fully translate to living animals. Yet something important did happen: the mice treated with naringenin showed dramatically less liver fibrosis than their untreated counterparts. Staining techniques that highlight collagen—the protein that accumulates during fibrosis—revealed that naringenin reduced the scarred area of the liver. Blood tests showed improved liver function markers. Tissue samples examined under the microscope confirmed that naringenin had significantly lessened the hepatic injury caused by the infection.
To understand how naringenin achieved this protection, the researchers analyzed the molecular machinery of liver fibrosis. When Schistosoma eggs lodge in the liver, they trigger immune cells to release inflammatory molecules that activate hepatic stellate cells—specialized cells that normally help repair liver damage but, when chronically activated, become collagen factories. Naringenin suppressed the expression of transforming growth factor-beta, a master switch that turns on stellate cell activation, and reduced levels of alpha-smooth muscle actin and collagen itself. The compound also dampened the inflammatory cascade: it lowered expression of inducible nitric oxide synthase and reduced two key inflammatory cytokines, IL-1 beta and IL-18. Additionally, naringenin appeared to ease the oxidative stress that accumulates during chronic parasitic infection, allowing the body's own antioxidant defenses to relax.
The findings suggest a path forward, though not yet a complete solution. Naringenin alone cannot eliminate the parasites as effectively as praziquantel does. But it may do something praziquantel cannot: reverse the fibrosis and inflammation that persist even after the worms are dead. The researchers propose that combining the two drugs—using praziquantel to kill the parasites and naringenin to heal the damaged liver—could offer patients a more complete recovery. Such a combination therapy remains theoretical for now, but the laboratory evidence points toward a future where schistosomiasis, long a sentence of progressive organ failure, might become a treatable and reversible disease.
Notable Quotes
Although praziquantel is effective in eliminating adult schistosomes, it does not remove the deposited eggs within host tissues, nor does it reverse the established organ fibrosis.— Study authors, PLOS Neglected Tropical Diseases
Co-administration of praziquantel and naringenin may not only enhance the elimination of adult worms but also promote the reversal of liver fibrosis caused by Schistosoma mansoni infection.— Study authors, discussing future therapeutic strategy
The Hearth Conversation Another angle on the story
Why does praziquantel, the drug that already works, not solve this problem?
Praziquantel is excellent at one thing: killing the adult worms. But by the time someone gets treated, the eggs have already done their damage. The liver is already scarring. Praziquantel doesn't reverse that scarring, and it doesn't stop the inflammation that keeps building even after the worms are gone.
So naringenin is meant to fix what praziquantel leaves broken?
Exactly. In the lab, naringenin damaged the worms too, which was surprising. But in living mice, that effect faded. What didn't fade was its ability to calm the inflammation and stop the liver from turning into scar tissue. It works on the aftermath, not the parasite itself.
The mice still had eggs in their livers even after naringenin treatment. How is that a success?
Because the eggs alone don't kill you—the fibrosis does. The immune system's reaction to the eggs is what hardens the liver into cirrhosis. If you can stop that reaction, you buy time and prevent the worst outcomes, even if the eggs are still there.
What happens if you give both drugs together?
That's the bet. Praziquantel eliminates the worms quickly. Naringenin quiets the inflammation and reverses the scarring that's already happened. Theoretically, you get parasite elimination plus actual healing of the organ. No one has tested it yet, but the logic is sound.
Is naringenin safe? It's just from citrus fruit, right?
It's a natural compound, yes, but that doesn't automatically mean it's safe at therapeutic doses. The study used it in mice at specific concentrations. Human trials would need to establish safety and dosing. But the fact that it comes from food is a reasonable starting point for development.